



Source details

Asian Pacific Journal of Tropical Medicine

Scopus coverage years: from 2010 to Present

Publisher: Wolters Kluwer Health

ISSN: 1995-7645 E-ISSN: 2352-4146

Subject area: Medicine: General Medicine

Source type: Journal

CiteScore 2021

3.3



SJR 2021

0.402



SNIP 2021

0.946



[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

Improved CiteScore methodology



CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021

$$3.3 = \frac{1,085 \text{ Citations 2018 - 2021}}{324 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022

$$3.7 = \frac{1,134 \text{ Citations to date}}{303 \text{ Documents to date}}$$

Last updated on 05 April, 2023 • Updated monthly

CiteScore rank 2021

Category	Rank	Percentile
Medicine		
General Medicine	#178/826	78th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)



Asian Pacific Journal of Tropical Medicine

COUNTRY[India](#)Universities and
research institutions in
India

Media Ranking in India

**SUBJECT AREA AND
CATEGORY**[Medicine](#)
[Medicine](#)
(miscellaneous)**PUBLISHER**[Wolters Kluwer Medknow
Publications](#)**H-INDEX****67****PUBLICATION TYPE**[Journals](#)**ISSN**

23524146, 19957645

COVERAGE

2010-2022








INFORMATION[Homepage](#)[How to publish in this
journal](#)[daouda.sissoko@u-
bordeaux.fr](mailto:daouda.sissoko@u-bordeaux.fr)**SCOPE**

Asian Pacific Journal of Tropical Medicine (ISSN 1995-7645 CODEN: APJTB6), a publication of Editorial office of Hainan Medical University, is a peer-reviewed print + online Monthly journal. The journal's full text is available online at <http://www.apjtm.org/>. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. APJTM aims to provide an academic communicating platform for international physicians, medical scientists, allied health scientists and public health workers, especially those of the Asia-Pacific region and worldwide on tropical medicine, infectious diseases and public health, and to meet the growing challenges of understanding, preventing and controlling the dramatic global emergence and re-emergence of infectious diseases in the Asia-Pacific.

 Join the conversation about this journal

FIND SIMILAR JOURNALS ?


<p>1 Asian Pacific Journal of Tropical Biomedicine NLD</p> <p>62% similarity</p>	<p>2 Tropical Journal of Pharmaceutical Research NGA</p> <p>48% similarity</p>	<p>3 Pathogens and Global Health GBR</p> <p>47% similarity</p>	<p>4 BMC Compl Alternative I GBR</p> <p>4 s</p>
--	--	--	---



Year International Collaboration

800

Cited documents Uncited documents



Asian Pacific Journal of Tropical Medicine

Q3
Medicine (miscellaneous)
best quartile

SJR 2022
0.37

powered by scimagojr.com


Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com"
```

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.



Metrics based on Scopus® data as of April 2023

B Bo Cui 3 years ago

the journal is published monthly

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Sir/Madam, thanks for your participation! Best Regards, SCImago Team

E Emeka Mgbe 3 years ago

Pls what is the frequency of publishing of this journal.Thanks

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Emeka,
thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you visit the journal's



Impact Factor 2021: 3.041 (@Clarivate Analytics)
 5-Year Impact Factor: 2.776 (@Clarivate Analytics)
 Impact Factor Rank: 10/24, Q2 (Tropical Medicine)

Search **GO**
 Advanced Search

Users Online: 312

[About Journal](#) [Articles](#) [Ahead of Print](#) **NEW** [Authors](#) [Search](#) [Subscribe](#) [Contact Us](#) [Reader Login](#)

Advisory and Editorial Board

[About the journal](#)

Advisory Board

Dirk Engels, PhD

Former Director of Control of Neglected Tropical Diseases World Health Organization

Marcel Tanner, PhD, MPH

Swiss Academy of Sciences; University of Basel, Basel, Switzerland

Editorial Board

Kamel Adwan, PhD

Department of Biology and Biotechnology, An-Najah N. University, West-Bank, Palestine

Mahboob Alam, PhD

Department of Internal Medicine, Division of Cardiology, Baylor College of Medicine, Houston, USA

Silvia Angeletti, PhD

Clinical Pathology and Microbiology Laboratory, University Hospital Campus Bio-Medico of Rome, Rome, Italy

Herbert Auer, PhD

Department of Medical Parasitology, Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria

Majid Avijgan, PhD

Traditional Persian-Iranian Medicine, Department of Infectious Diseases, Isfahan University of Medical Sciences, Isfahan, Iran

Ciomar Aparecida Bersani-Amado, PhD

Department of Pharmacology and Therapeutic, State University of Maringá, Paraná, Brazil

Ioan Stelian Bocsan, PhD

Epidemiology and Primary Health Care Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Norbert W. Brattig, PhD

Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany

Jong-Yil Chai, PhD

Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul, Korea

Supat Chamnanchanunt, PhD

Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

[SUBMIT ARTICLE](#)

[SUBSCRIBE](#)

[POPULAR ARTICLES](#)

[JOIN AS REVIEWER](#)

[GET EMAIL ALERTS](#)

[RECOMMEND](#)

Jae Sue Choi, PhD

Department of Food Science and Nutrition, Pukyong National University, Busan, Korea

Massimo Ciccozzi, PhD

Department of Infectious Parasitic and Immunomediated Diseases, National Institute of Health in Italy, Rome, Italy

Luisa Custodio, PhD

Faculty of Sciences and Technology, Centre of Marine Sciences, University of Algarve, Faro, Portugal

Kusal K Das, PhD

Department of Physiology, Faculty of Medicine, BLDE University, Bijapur, India

Nicholas PJ Day, PhD

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Valentina Virginia Ebani, PhD

Department of Veterinary Science, University of Pisa, Pisa, Italy

Jimmy Thomas Efird, PhD

Brody School of Medicine, East Carolina University, Greenville, USA

Farouk M. F. El-Sabban, PhD

Department of Family Sciences, Department of Food Science and Nutrition, College of Life Sciences, Kuwait University, Safat, Kuwait

Mma Ma A. Faridi, PhD

Department of Pediatrics, University College of Medical Sciences, Delhi University and GTB Hospital, New Delhi, India

Folorunso Oludayo Fasina, PhD

Food and Agricultural Organization of the United Nation, Dar es Salaam, Tanzania

Guido Favia, PhD

School of Bioscience and Veterinary Medicine, University of Camerino, Camerino, Italy

Bernhard Fleischer, PhD

Institute for Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Mun Yik Fong, PhD

Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Owunari Abraham Georgewill, PhD

Department of Pharmacology and Toxicology, University of Port Harcourt, Port Harcourt, Nigeria

Antonio Gomez-Muñoz, PhD

Facultad de Ciencia y Tecnología, Departamento de Bioquímica y Biología Molecular, Universidad del País Vasco, Bilbao, Spain

Exnevia Gomo, PhD

Department of Medical Laboratory Sciences, University of Zimbabwe, Harare, Zimbabwe

Stephen Brian Gordon, PhD

Liverpool School of Tropical Medicine, Institute of Infection & Global Health, University of Liverpool, Liverpool, UK

Robert A. Harrison, PhD

Alistair Reid Venom Research Unit, Parasitology Department, Liverpool School of Tropical Medicine, Merseyside, UK

Yasushi Hasegawa, MD

Department of Surgery, School of Medicine, Iwate Medical University, Morioka, Japan

Andrey Karlyshev, PhD

Life Sciences, Pharmacy & Chemistry, Kingston University, Kingston, UK

Asad Ullah Khan, PhD

Medical Microbiology and Molecular Biology Laboratory, Aligarh Muslim University, Aligarh, India

Hamzullah Khan, PhD

Department of Pathology, Gomal Medical College, Dera Ismail Khan, Pakistan

Remington Lee, PhD

Department of Mental Health, Bloomberg School of Public Health, Nevin Johns Hopkins University, Baltimore, USA

Rosemary Susan Lees, PhD

Liverpool Insect Testing Establishment (LITE), Vector Biology Department, Liverpool School of Tropical Medicine, Liverpool, UK

Usa Lek-Uthai, PhD

Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok, Thailand

Sutherland Maciver, PhD

Centre for Integrative Physiology, School of Medicine, University of Edinburgh, Edinburgh, UK

Richard James Maude, PhD

Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK

Nada Milic, PhD

Ministry of Health, Belgrade, Serbia

Fraser De Wolfe Miller, PhD

John A. Burns School of Medicine, University of Hawaii System, Honolulu, USA

Fawaz Mzayek, PhD

Division of Epidemiology, University of Memphis, School of Public Health, Memphis, USA

Veeranoot Nissapatorn, PhD

Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Francois Henry Nosten, PhD

Shoklo Malaria Research Unit, Mahidol-Oxford University Research Unit, Oxford University, Oxford, UK

Uchenna Nwagha, PhD

Department of Obstetrics and Gynaecology/Physiology, College of Medicine, University of Nigeria, Nsukka, Nigeria

Wen-huang Peng, PhD

Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Pharmacy, China Medical University, Taichung, Taiwan

Rasa Petraityte-Burkeikiene, PhD

Institute of Biotechnology, Department of Eukaryote Genetic Engineering Vilnius University, Vilnius, Lithuania

Michael Ramharter, PhD

Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria

Rajul Rastogi, PhD

Department of Radiodiagnosis, Teerthanker Mahaveer Medical College and Research Centre, Moradabad, India

Barbara Rath, PhD

Department of Pediatrics, Charite-Universitätsmedizin Berlin, Berlin, Germany

Eduardo Rocha, PhD

Interdisciplinary Center for Marine and Environmental Research (CIIMAR), CIMAR Associate Laboratory (CIMAR LA), University of Porto, Porto, Portugal

Alfonso J. Rodriguez-Morales, MD, PhD

Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Risaralda, Colombia

Abhay R. Satoskar, PhD

Departments of Pathology and Microbiology, Wexner Medical Center, the Ohio State University, Ohio, USA

Jitendra Kumar Saxena, PhD

Division of Biochemistry, CSIR-Central Drug Research Institute, Lucknow, India

Jonas Schmidt-Chanasit, PhD

Faculty of Mathematics, Informatics and Natural Sciences, Department of Biology, University of Hamburg, Hamburg, Germany

Mohamed Hussain Rezvi Sheriff, PhD

Faculty of Medicine, Department of Clinical Medicine, University of Colombo, Colombo, Sri Lanka

Ajit Singh, PhD

Department of Immunology, College of Veterinary Science, Lala Lajapat Rai University of Veterinary and Animal Sciences, Hisar, India

Duncan R. Smith, PhD

Institute of Molecular Biosciences, Mahidol University, Nakorn Pathom, Thailand

Kabkaew L. Sukontason, PhD

Department of Parasitology, Chiang Mai, Thailand

Mohsen Tafaghodi, PhD

School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Léon Tshilolo, PhD

Centre Hospitalier Monkole, Kinshasa, Congo

Vijaya Lakshmi Valluri, PhD

Immunology and Molecular Biology Division, LEPRASOCIETY-Blue Peter Public Health & Research Centre, Secunderabad, India

Luca Vannucci, PhD

Laboratory of Tumor Biology, Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Libechev, Czech Republic

Lee Yeong Yeh, PhD

School of Medical Sciences, Universiti Sains Malaysia (USM), Kelantan, Malaysia

Rong-xin Zhang, PhD

Laboratory of Immunology and Inflammatory Diseases, Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, China



Impact Factor 2021: 3.041 (@Clarivate Analytics)
 5-Year Impact Factor: 2.776 (@Clarivate Analytics)
 Impact Factor Rank: 10/24, Q2 (Tropical Medicine)

Search GO
 Advanced Search


Users Online: 321

- [About Journal](#)
- [Articles](#)
- [Ahead of Print NEW](#)
- [Authors](#)
- [Search](#)
- [Subscribe](#)
- [Contact Us](#)
- [Login](#)

Table of Contents

[Next Issue](#)

[Previous Issue](#)



September 2021

Volume 14 | Issue 9

Page Nos. 381-428

Online since Tuesday, September 28, 2021

Accessed 16,967 times.

PDF access policy

Journal allows immediate open access to content in HTML + PDF

[View issue as eBook](#)

[Issue citations](#)

[Issue statistics](#)

[RSS](#)

[SUBMIT ARTICLE](#)

[SUBSCRIBE](#)

[POPULAR ARTICLES](#)

[JOIN AS REVIEWER](#)

[GET EMAIL ALERTS](#)

[RECOMMEND](#)

- [Show all abstracts](#)
- [Show selected abstracts](#)
- [Export selected to](#) ▼
- [Add to my list](#)

COMMENTARY



Healthy tourism initiative in the age of COVID-19 in Indonesia


p. 381

I Md Ady Wirawan, I Nyoman Sutarsa, Putu Ayu Swandewi Astuti

DOI:10.4103/1995-7645.326258

[\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(1\)\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}

PERSPECTIVE



Wolbachia-infected mosquitoes: The answer to the dengue endemic in Pakistan?

p. 383

Qazi Syed Muhammad Ali, Mustafa Ashiq Husain

DOI:10.4103/1995-7645.326259

[\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(1\)\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}

REVIEW ARTICLES



Foodborne parasitic diseases in China: A scoping review on current situation, epidemiological trends, prevention and control

Langui Song, Qingxing Xie, Zhiyue Lv

DOI:10.4103/1995-7645.326252

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(1\)\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}

COVID-19-associated mucormycosis and treatments


p. 401

Vetrivelvan Subramaniyan, Shivkanya Fuloria, Hari Kumar Darnal, Dhanalekshmi Unnikrishnan Meenakshi, Mahendran Sekar, Rusli Bin Nordin, Srikumar Chakravarthi, Kathiresan V Sathasivam, Shah Alam Khan, Yuan Seng Wu, Usha Kumari, Kalvatala Sudhakar, Rishabha Malviya, Vipin Kumar Sharma, Neeraj Kumar Fuloria

DOI:10.4103/1995-7645.326253

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(4\)\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}

ORIGINAL ARTICLES




Seroprevalence of anti-HBs antibodies and the need for booster vaccination in children under 5 years of age born to HBsAg-negative mothers

Jannatin Nisa Arnindita, Muhammad Miftahussurur, Bagus Setyoboedi, Juniastuti

DOI:10.4103/1995-7645.326255

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}




Predictive modeling of 30-day readmission risk of diabetes patients by logistic regression, artificial neural network, and EasyEnsemble

Xiyu Xiang, Chuanyi Liu, Yanchun Zhang, Wei Xiang, Binxing Fang

DOI:10.4103/1995-7645.326254

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Citations \(1\)\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}



Original Article

Asian Pacific Journal of Tropical Medicine

doi: 10.4103/1995–7645.326255

5-Year Impact Factor: 2.285

Seroprevalence of anti-HBs antibodies and the need for booster vaccination in children under 5 years of age born to HBsAg–negative mothers

Jannatin Nisa Arnindita¹, Muhammad Miftahussurur², Bagus Setyoedi³, Juniastuti⁴✉

¹Medical School, Faculty of Medicine, Universitas Airlangga, Indonesia

²Department of Internal Medicine, Dr. Soetomo General Hospital/Faculty of Medicine, Universitas Airlangga, Indonesia

³Department of Pediatrics, Dr. Soetomo General Hospital/Faculty of Medicine, Universitas Airlangga, Indonesia

⁴Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Indonesia

ABSTRACT

Objective: To determine the proportion of HBV surface antigen (anti-HBs) antibody positive children under five years of age born to HBsAg-negative mothers and to analyze the possible related factors following implementation of a hepatitis B vaccination program for infants in Indonesia 22 years ago.

Methods: Blood samples were taken from children under five years of age born to HBsAg-negative mothers who have completed primary vaccination series. Anti-HBs antibodies were determined by using rapid test. Data of age, gender, nutritional status, vaccination timing or vaccination compliance, and booster vaccination were collected from vaccination card.

Results: Ninety children were enrolled, consisting of 47 females and 43 males with a mean age of 2.3 years. Twenty two (24.4%) children received booster vaccine between 18 and 24 months and 55 (61.1%) were anti-HBs positive. Among factors of age, gender, nutritional status, compliance to vaccination and booster vaccine, only administration of booster vaccine was significantly associated with anti-HBs status (*OR* 5.45, 95% *CI* 1.45, 20.52). Children who received booster vaccine at age of 18-24 months were 5.45 times more likely to be anti-HBs positive than that of children who did not receive booster vaccine.

Conclusions: Booster vaccine rate is low among children under 5 years of age but is associated with anti-HBs positivity. Booster vaccination may be required to improve anti-HBs seropositivity.

KEYWORDS: Hepatitis B vaccination; Booster vaccine; Children under five years

1. Introduction

Indonesia has been considered as a country with moderate to high hepatitis B endemicity[1]. Prevention of hepatitis B infection in infants requires special attention because transmission from-mother-to-child is the majority cause of the chronic infections, especially in countries with high level of endemicity such as Indonesia[2]. The development of chronic infection is very common in infants infected from their mothers or by horizontal transmission before the age of five years[3]. The younger the age at which the infection is acquired, the greater the predisposition to the carrier state, chronic liver disease and subsequent development of cirrhosis and hepatocellular carcinoma[4,5]. Vaccination for infants and children is the most efficient method in providing long-term protection against hepatitis

Significance

This study shows that less than two thirds of vaccinated children under five years of age are anti-HBs positive. Booster vaccine at age of 18-24 months is significantly associated with anti-HBs seropositivity. The administration of booster vaccines in accordance with national immunization policy should be routinely performed and monitored.

✉To whom correspondence may be addressed. E-mail: junssf@fk.unair.ac.id

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

©2021 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer-Medknow. All rights reserved.

How to cite this article: Arnindita JN, Miftahussurur M, Setyoedi B, Juniastuti. Seroprevalence of anti-HBs antibodies and the need for booster vaccination in children under 5 years of age born to HBsAg-negative mothers. Asian Pac J Trop Med 2021; 14(9): 410-416.

Article history: Received 16 February 2021
Accepted 1 September 2021

Revision 21 July 2021
Available online 28 September 2021

B virus (HBV) infection[6,7].

In 1992, the World Health Organization (WHO) established a goal for all countries with HBV carrier rates of over 8% to integrate hepatitis B vaccination into their routine immunization programs by 1995 and for all countries to establish such programs by 1997[8]. Taiwan is perhaps one of the regions showing the best success from universal hepatitis B immunization, as reported that 9.8% children under 15 years old in Taiwan were HBV carriers[9], then 30 years after vaccination program (2004) had been implemented, the number significantly decreased to 0.9%[10].

In Indonesia, the universal hepatitis B vaccination program has been implemented since 1997 and it was reported that the prevalence of HBsAg decreased from 9.4% in 2007 to 7.2 % in 2013[1]. In 1997, a recombinant hepatitis B vaccine replaced plasma-derived vaccine[11,12]. In 1999, Indonesia introduced an innovative policy by using a prefilled single-use injection device of hepatitis B vaccine that is stable even when placed outside the cold chain. This approach has improved hepatitis B vaccine coverage and reduced hepatitis B carrier rates[13]. In 2000, Indonesia introduced a program for using the device for the birth dose in seven provinces and in 2003 the program expanded to target all of Indonesia's five million annual births[14].

Previous studies reported that some factors related to antibody against HBV surface antigen (anti-HBs) development after vaccination include age, gender, nutritional status, vaccination compliance and booster vaccination[15-19], however, similar studies in Indonesia are still limited. Data from Elementary Health Research, Indonesia showed that higher anti-HBs titer existed in male population than female, but age factor had higher significance with anti-HBs titer than gender factor[20]. Difference in nutritional status also has an impact on anti-HBs (immune response) as reported that children with marasmus and kwashiorkor showed significantly poorer response than healthy children in Egypt[17]. Currently, national program in Indonesia implements four weeks interval for each dose of vaccine primary series. A systematic study revealed that longer vaccination interval showed higher final anti-HBs concentrations while other studies conducted in Padang found no difference between different vaccination schedules[21,22]. Booster vaccine was considered unnecessary in immunocompetent children after primary doses, while a recent study found that around more than a third of children who have received three doses of primary vaccine series were low and non-responders, thus needed additional booster vaccine[18,19]. Plenty debates about vaccine schedules and doses are still ongoing while birth dose remained as a crucial determinant of vaccine immune reaction as children without birth dose proved to be 3.5 times more likely to be infected with hepatitis B[23].

Vaccination against HBV immediately after birth prevents neonatal

infection which transmitted vertically by HBV carrier mothers[24]. However, if the mother is HBsAg negative, the infant may still be exposed to HBV postnatally from another family member or caregiver. This occurs in two-thirds of the cases of childhood transmission, especially in high endemicity countries[25]. A previous study showed that immunization of newborns does not only protect vaccinated children but also decreases horizontal transmission as children do not form a reservoir anymore for virus transmission at school and at home to susceptible adults[26]. Meanwhile, children born to HBsAg-positive mothers showed high positivity of anti-HBs might be due to hepatitis B infection occur through vertical transmission[27], or simply there were some amounts of anti-HBs delivered[28]. These children might also show poor immune response to HB vaccine due to hepatitis B immunoglobulin (HBIG) administration[29].

Sidotopo Wetan, a district in Surabaya (a capital of East Java province, Indonesia) has performed a national vaccination program and reached up to 99.78% coverage for hepatitis B vaccine in 2017 but it was ranked as the area with the greatest number (9.6% of 219 positive cases) of HBsAg prevalence in Surabaya[30]. The aim of this study was to determine the proportion of anti-HBs positive in children under five years of age born to HBsAg-negative mothers who have completed primary hepatitis B vaccination series in Sidotopo Wetan and to analyze the possible related factors.

2. Subjects and methods

2.1. Ethical approval

Ethical clearance of this study was obtained from Ethical Committee of Faculty Medicine, Universitas Airlangga, Indonesia (No.100/EC/KEPK/FKUA/2019). Written informed consent was obtained by the parents or guardians of each child.

2.2. Sample and data collection

In this cross-sectional study, children aged 1-<5 years who attended Sidotopo Wetan Primary Health Care were enrolled. Participants recruitment, sample and data collection were conducted from May to July 2019. Inclusion criteria were children who have completed hepatitis B primary vaccination series (four doses) which was recorded in the vaccination card. Exclusion criteria were children born to HBsAg-positive mothers or received HBIG after birth. A total of 100 participants was obtained, but it was eliminated into 90 samples due to missing data in their vaccination cards.

Data obtained from vaccination cards include age, gender, nutritional status (WHO weight/age chart), vaccination timing or

Table 1. Characteristic and vaccination data of all 90 children.

Characteristics and vaccination	1-<2 (years) (n=31)	2-<3 (years) (n=17)	3-<4 (years) (n=26)	4-<5 (years) (n=16)	Total (n=90)
Gender, n (%)					
Female	15 (48.4)	11 (64.7)	11 (42.3)	10 (62.5)	47 (52.2)
Male	16 (51.6)	6 (35.3)	15 (57.7)	6 (37.5)	43 (47.8)
Age (mean±SD, years)	1.6±0.3	2.5±0.3	3.5±0.3	4.4±0.2	2.3±1.1
Nutritional status, n (%)					
Severely underweight	2 (6.5)	1 (5.9)	4 (15.4)	1 (6.3)	8 (8.9)
Underweight	6 (19.4)	6 (35.3)	5 (19.2)	6 (37.5)	23 (25.6)
Normal weight	23 (74.2)	10 (58.8)	17 (65.4)	9 (56.3)	59 (65.6)
Compliance to vaccination schedule, n (%)					
Compliant	11 (35.5)	5 (29.4)	10 (38.5)	5 (31.3)	31 (34.4)
Incompliant	20 (64.5)	12 (70.6)	16 (61.5)	11 (68.8)	59 (65.6)
Booster vaccine at age 18-24 months, n (%)					
Yes	9 (29.0)	5 (29.4)	5 (19.2)	3 (18.8)	22 (24.4)
No	22 (71.0)	12 (70.6)	21 (80.8)	13 (81.3)	68 (75.6)
Anti-HBs (+), n (%)	19 (61.3)	12 (70.6)	13 (50.0)	11 (68.8)	55 (61.1)

Nutritional status was calculated as weight/age.

vaccination compliance with a schedule of 0, 2, 3, 4 months in age (based on national vaccination program), also booster vaccination[31].

Capillary blood samples were drawn using finger-prick method and examined the anti-HBs status using MONOTES® HBsAb Rapid Test Cassette (PT. Bintang Mono, Tangerang, Banten, Indonesia). Approximately 5-10 drops amount of blood was transferred to the cassette then the result appeared after 15-30 minutes. The sample was considered positive if anti-HBsAg ≥10 mIU/mL.

2.3. Statistical analysis

Statistical analysis was performed using The IBM SPSS® software (Statistical Package for Social Sciences, Inc., Chicago, IL) using Fisher's exact test and logistic regression test. The obtained association was further analyzed using odds ratio. $P \leq 0.05$ was considered to indicate a statistically significant difference.

3. Results

A total of 90 children under five years of age born to mothers with HBsAg negative were enrolled, consisting of 47 (52.2%) females and 43 (47.8%) males with a mean age of 2.3 years. A total of 55 children (61.1%) were anti-HBs positive and the rest (38.9%) were anti-HBs negative. There was a fluctuation of percentage of anti-HBs-positive children to age range respectively as follows: 61.3% in those aged 1-<2 years, 70.6% in those aged 2-<3 years, 50.0% in those aged 3-<4 years and 68.8% in those aged 4-<5 years (Table 1).

Characteristics (age, gender, nutritional status) and vaccination information (compliance and booster vaccine) of the children based on age range were shown (Table 1). The majority of the children were classified as normal-weight (65.6%), followed by underweight (25.6%) and severely underweight (8.9%). No child was obese. Most children (65.6%) were not vaccinated on a schedule and variations in the timing of vaccine administration are shown in Table 2. Besides, most children (75.6%) did not receive booster vaccine at age 18-24 months (Table 1).

Table 2. Vaccination timing variation of samples.

Timing (in months age)	n	%
0, 2, 3, 4 [†]	31	34.4
0, 2, 3, 5	12	13.3
0, 2, 3, 6	5	5.6
0, 2, 4, 5	4	4.4
0, 2, 4, 6	4	4.4
0, 3, 4, 5	4	4.4
0, 3, 4, 6	2	2.2
Others [‡]	28	31.1

[†]Recommended schedule. [‡]Others means other 28 vaccination timings as follows: 0, 2, 9 months (all monovalent doses); 0, 1, 2, 6 months; 0, 1, 2, 7 months; 0, 1, 3, 4 months; 0, 2, 3, 7 months; 0, 2, 3, 8 months; 0, 2, 3, 11 months; 0, 2, 3, 17 months; 0, 2, 4, 8 months; 0, 2, 4, 9 months; 0, 2, 5, 6 months; 0, 2, 5, 7 months; 0, 2, 5, 8 months; 0, 2, 6, 7 months; 0, 2, 7, 10 months; 0, 2, 11, 11 months; 0, 3, 3, 4 months; 0, 3, 4, 11 months; 0, 4, 5, 6 months; 0, 4, 7, 8 months; 0, 5, 7, 9 months; 0, 6, 7, 8 months; 0, 6, 7, 9 months; 0, 7, 8, 10 months; 2, 3, 4, 15 months; 2, 3, 4, 21 months; 0, 4, 11, 12 months; 0, 5, 11, 12 months.

Among those factors (age, gender, nutritional status, compliance to vaccination, and booster vaccine), only administration of booster vaccine at age of 18-24 months was significantly associated with anti-HBs status ($P=0.012$). Children who received booster vaccine at age of 18-24 months was 5.45 times more likely to have anti-HBs positive than those who did not receive booster vaccine ($P \leq 0.05$, OR 5.45, 95% CI 1.45, 20.52) (Table 3). Based on age groups, the seropositivity rate of anti-HBs in children who received booster vaccine ranged 60%-100%, greater than that in children who did not receive booster vaccine (range 42.9%-75.0%) (Table 4). The coverage of booster vaccine was only about 18.8%-29.4% in all age groups and most children received only one booster dose (Table 3 and 4).

4. Discussion

According to the national immunization policy in Indonesia, the single birth dose of the hepatitis B vaccine should be given within

Table 3. Binary logistic regression analysis of variables for association with anti-HBs seropositivity of all children.

Factors	Total	anti-HBs(+) (n=55) [n (%)]	anti-HBs(-) (n=35) [n (%)]	P	OR	95% CI
Age						
1-<2 years [#]	31	19 (34.6)	12 (34.3)			
2-<3 years	17	12 (21.8)	5 (14.3)	0.480	0.62	(0.16, 2.37)
3-<4 years	26	13 (23.6)	13 (37.1)	0.608	1.34	(0.44, 4.15)
4-<5 years	16	11 (20.0)	5 (14.3)	0.415	0.56	(0.14, 2.24)
Gender						
Female	47	29 (52.7)	18 (51.4)	0.808	1.12	(0.46, 2.75)
Male [#]	43	26 (47.3)	17 (48.6)			
Nutritional status						
Normal weight [#]	59	38 (69.1)	21 (60.0)			
Underweight	23	14 (25.5)	9 (25.7)	0.602	1.33	(0.45, 3.91)
Severely underweight	8	3 (5.4)	5 (14.3)	0.408	1.96	(0.40, 9.63)
Compliance to vaccination schedule						
Compliant ^{*#}	31	19 (34.5)	12 (34.3)			
Incompliant	59	36 (65.5)	23 (65.7)	0.899	0.94	(0.36, 2.44)
Booster vaccine at 18-24 months						
Yes [#]	22	19 (34.5)	3 (8.6)			
1 dose	19	16 (84.2) [†]	3 (100) [†]			
>1 dose	3	3 (15.8) [†]	0 (0) [†]			
No	68	36 (65.5)	32 (91.4)	0.012 [‡]	5.45	(1.45, 20.52)
Total	90	55 (100)	35 (100)			

^{*}Compliant means that samples were vaccinated according to recommended schedule (at 0, 2, 3, 4 months of age) from government. [†]The percentage was calculated using the total number of children who received booster vaccine as a denominator for each anti-HBs status. Binary logistic regression analysis was used to measure P value, OR (odds ratio), and 95% CI (95% confidence interval) with [#]reference group for each category. [‡]Significant difference between samples with booster vaccine and those without booster vaccine.

Table 4. Coverage of booster vaccine and anti-HBs seropositivity in children who received booster vaccine and those who did not receive booster vaccine according to age range.

Age (years)	N	Coverage of booster vaccine [n (%)]	Anti-HBs (+) in children who received booster vaccine [n (%)]	Children without booster vaccine [n (%)] [^]	Anti-HBs (+) in children who did not receive booster vaccine [n (%)]
1-<2	31	9 (29.0)	9 (100.0)	22 (24.4)	10 (45.5)
2-<3	17	5 (29.4)	3 (60.0)	12 (13.3)	9 (75.0)
3-<4	26	5 (19.2) ^{&}	4 (80.0)	21 (23.3)	9 (42.9)
4-<5	16	3 (18.8) [‡]	3 (100.0)	13 (14.4)	8 (61.5)
Total	90	22 (24.4)	19 (86.4)	68 (75.6)	36 (52.9)

[&]Two children received first and second booster doses at 19 and 27 months and at 18 and 30 months, respectively. [‡]One child received first and second booster doses at 19 and 24 months. [^]The percentage was calculated using the total number of children (N) as a denominator. Fisher's exact test was used. P=0.596.

seven days after birth and should be followed by three doses of combined vaccines including diphtheria, pertussis, tetanus and hepatitis B within the 2nd, 3rd, and 4th months (DPT-HB3)[32]. The policy also recommends the implementation of varied vaccine booster doses between 1 and 3 doses, with one booster dose implemented in national program, while children in certain area could receive 1-2 more booster doses when there was an outbreak of diphtheria, pertussis, tetanus, hepatitis B or *Haemophilus influenzae*.

Hepatitis B vaccination succeeded in covering a large population as it reached 91.7%, surpassed the target by 90% in 2017 in Indonesia[33]. In the study in Sidotopo Wetan district, among 90 vaccinated children under five years of age born to HBsAg-negative mothers, only 61.1% of them appeared to be positive for anti-HBs. Similarly, the previous study held in Yogyakarta, Indonesia involving 57 infants and children aged five months-five years reported that protective anti-HBs titer was only shown by 73.1% samples[34]. These data contradicts data from WHO which showed that more than 95% infants, children, and adolescents who have completed hepatitis B vaccination doses will remain positive for anti-HBs for at least 20 years[3]. Due to the discrepancy, we investigated the possible factors

influencing the low seropositivity of anti-HBs in this study.

This study showed fluctuating trend of anti-HBs-positive children percentage by age range (no significant difference) as follows: 61.3% in those aged 1-<2 years, 70.6% in those aged 2-<3 years, 50.0% in those aged 3-<4 years and 68.8% in those aged 4-<5 years. It differed from a previous study in children aged eight months-five years in Bantul city, Indonesia, which reported that anti-HBs seropositivity was negatively correlated with age, although the correlation was weak. The seropositivity rate (anti-HBs \geq 10 mIU/mL) in children aged one year was 100% and in children aged 5 years was 37%[35]. The results of another study in Taiwan showed that the seropositivity rate of anti-HBs declined from 99% at one year of age to 83% at 5 years of age[36] and further dropped to 71.1% at 7 years of age, 37.4% at 12 years of age and 37% at 15-17 years of age[37]. Further investigation is needed towards the unexpected result in Sidotopo Wetan. Some potential factors such as host (e.g. comorbidities), extrinsic (e.g. preexisting immunity, infections) and vaccine (e.g. vaccine strain and vaccine quality) could be considered[38].

No statistically difference between gender and anti-HBs seropositivity observed in this study, which was similar to other

studies[39–41]. Kwon and Jeong added that there was no statistically significant difference in the anti-HBs seropositivity rate based on gender in any age groups[41].

The immune status of an individual is well known as an important factor influencing antibody production. Our study showed that more children with normal weight (69.1%) performed anti-HBs positive than underweight/severely underweight children ($P>0.05$). Similar results by other studies in varied population[42–44] reported that children with anti-HBs positive had better nutritional status compared to children in non-reactive group, but not significantly different. However, Kwon and Jeong showed a significant correlation between anti-HBs titer and body mass index (BMI) after the adjustment for age and sex. They indicated that BMI is a potential factor affecting anti-HBs titer in healthy children[41]. Variation and limitation of those studies might contribute the obtained results.

WHO recommended universal provision of three doses of hepatitis B vaccine for infants and universal birth dose vaccine. The birth dose of hepatitis B vaccine can be given only as monovalent hepatitis B vaccine, as diphtheria, pertussis, and tetanus vaccine is not recommended before the age of four weeks[45]. However, there has not been any standard vaccine schedule. Different countries apply varied hepatitis B schedules in their national vaccination program, for instance in China, hepatitis B vaccination is given in three separated doses for infants aged 0, 1, and 6 months, while in Germany, it is given in four separated doses for infants aged 2, 3, 4, and 11–14 months[46,47]. Indonesia prioritizes compliance and completeness of vaccine administration in consecutive months at age 0, 2, 3, and 4 months then followed by booster vaccine at age 18–24 months. Most children (65.6%) in Sidotopo Wetan were not vaccinated on schedule. More children who were not vaccinated on schedule (65.5%) had anti-HBs positive than children who were vaccinated on schedule (34.5%) although there was no significant difference between schedule and anti-HBs seropositivity. In previous reports, no apparent effect on immunogenicity has been documented when minimum spacing of doses is not achieved precisely, while increasing the interval between the first two doses has little effect on immunogenicity or final antibody concentration. The third dose confers the maximum level of seroprotection but acts primarily as a booster and appears to provide optimal long-term protection. Longer intervals between the last two doses result in higher final antibody levels but might increase the risk for acquisition of HBV infection among persons who have a delayed response to vaccination[48].

CDC reported that after primary hepatitis B vaccination, anti-HBs concentrations declined rapidly within the first year and more slowly thereafter[48]. A cohort study of hepatitis B vaccine in an endemic area of hepatitis B suggested to offer a second booster, five years after the first booster (one year after primary vaccination) to reach maximum protection[49]. Booster vaccine can significantly increase anti-HBs titer in individuals who did not respond to hepatitis B vaccination and restore decreased anti-HBs to provide long-term protection against HBV[3,50,51]. Booster vaccine is proved to further stimulate T follicular helper cells (Tfh) to produce more B cells and

antibody against hepatitis B infection[52]. When immune memory was present, the anti-HBs responses could be induced as early as one week following a booster, and such responders were likely to have protective titers after a single dose. The production of anti-HBs titers ≥ 10 mIU/mL one month after booster vaccination may result from either a primary immune response or anamnestic response[53]. A previous study revealed that one dose of booster vaccine was enough to restore lost antibody while another study indicated that three booster doses were required to give seroprotection against HBV infection[50,54]. Even primary dose vaccines alone had been proved to decrease HBsAg prevalence, some studies failed to prove that increased anti-HBs seroconversion after booster vaccine would decrease HBsAg prevalence[9,55–57]. Recommendations on booster vaccine in children are still lacking.

In Indonesia, booster vaccination has been routinely recommended in children aged 18–24 months between 1 and 3 doses, with one booster dose included in national program[32]; however, data explaining the protection of booster vaccine has not yet been available. This study showed administration of booster vaccine was significantly associated with anti-HBs status ($P=0.012$). A number of children received booster vaccine were around 5.45 times more likely to have anti-HBs positive. The greater seropositivity rate of anti-HBs was also seen in almost all age groups of children who received booster vaccine. However, it should be concerned why a minimum of one booster vaccine has not been implemented well in all age groups (range 18.8%–29.4%). They did not receive any booster vaccine until at the time of the study. This condition might contribute the finding of low percentage of anti-HBs positive.

There are some limitations in this study. This is only a pilot study. This study does not show the long-term follow up data (especially related with booster vaccine), therefore, the trend and the persistence of vaccine response (anti-HBs) by age could not be established well. Besides, only some factors associated with immune response to vaccine were evaluated. More other factors (not only host factors) such as extrinsic factors (*e.g.* preexisting immunity and infections/comorbidities) and vaccine factors will provide more comprehensive data. Furthermore, this study included participants in an area. It requires a surveillance study to assess hepatitis B vaccine protection (vaccine effectiveness) with a larger sample size in other regions.

In conclusion, only 61.1% vaccinated children born to HBsAg-negative mothers showed anti-HBs positive. Among factors of age, gender, nutritional status, compliance to vaccination and booster vaccine, only administration of booster vaccine was significantly associated with anti-HBs status. Accordingly, it was suggested to perform booster vaccine routinely according to the recommendation of the national immunization policy.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Authors' contributions

J and JNA designed this study. JNA conducted data collection and laboratory examination. J and JNA analyzed and interpreted the data and also drafted the manuscript. J, MM and BS contributed to the critical revision of the manuscript. All authors contributed to the final version of the manuscript. J supervised this study.

References

- [1] National Institute of Health Research and Development, Ministry of Health of Republic of Indonesia. *Basic Health Research (RISKESDAS) 2013*. [Online]. Available from: https://www.pusdatin.kemkes.go.id/resources/download/general/Hasil_Riskesdas_2013.pdf. [Accessed on 6 June 2020].
- [2] Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus. *Clin Gastroenterol Hepatol* 2019; **17**(10): 1929-1936.
- [3] World Health Organization. *Hepatitis B WHO Fact sheet*. [Online]. Available from: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>. [Accessed on 18 August 2019].
- [4] Ismail S, Hafez HA, Darweesh SK, Kamal KH, Esmat G. Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. *Ann Gastroenterol* 2014; **27**(4): 380-386.
- [5] Shaaban FA, Hassanin AI, Samy SM, Salama SI, Said ZN. Long-term immunity to hepatitis B among a sample of fully vaccinated children in Cairo, Egypt. *East Mediterr Heal J* 2007; **13**(4): 750-757.
- [6] Marshall H, Nolan T, Díez Domingo J, Rombo L, Sokal EM, Marès J, et al. Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. *Vaccine* 2010; **28**(27): 4411-4415.
- [7] Lu S, Ren J, Li Q, Jiang Z, Chen Y, Xu K, et al. Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization. *Hum Vaccines Immunother* 2017; **13**(4): 903-908.
- [8] Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. *Epidemiol Rev* 2006; **28**: 112-125.
- [9] Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: Impact and implication for future strategies. *Gastroenterology* 2007; **132**(4): 1287-1293.
- [10] Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. *World J Hepatol* 2015; **7**(18): 2127-2132.
- [11] Khan M, Dong JJ, Acharya SK, Dhagwahdorj Y, Abbas Z, Jafri SMW, et al. Hepatology issues in Asia: Perspectives from regional leaders. *J Gastroenterol Hepatol* 2004; **19**: S419-S430. doi: 10.1111/j.1440-1746.2004.03728.x.
- [12] Utsumi T, Yano Y, Lusida MI, Amin M, Soetjijpto, Hotta H, et al. Serologic and molecular characteristics of hepatitis B virus among school children in East Java, Indonesia. *Am J Trop Med Hyg* 2010; **83**(1): 189-193.
- [13] Nelson CM, Wibisono H, Purwanto H, Mansyur I, Moniaga V, Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: Evidence and solutions. *Bull World Health Organ* 2004; **82**(2): 99-105.
- [14] Levin CE, Nelson CM, Widjaya A, Moniaga V, Anwar C. The costs of home delivery of a birth dose of hepatitis B vaccine in a prefilled syringe in Indonesia. *Bull World Health Organ* 2005; **83**(6): 456-461.
- [15] Klinger G, Chodick G, Levy I. Long-term immunity to hepatitis B following vaccination in infancy: Real-world data analysis. *Vaccine* 2018; **36**(17): 2288-2292. doi: 10.1016/j.vaccine.2018.03.028.
- [16] Hu YC, Yeh CC, Chen RY, Su CT, Wang WC, Bai CH, et al. Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program. *Peer J* 2018; **6**: e4297. doi: 10.7717/peerj.4297.
- [17] El-Gamal Y, Aly RH, Hossny E, Afify E, El-Taliawy D. Response of Egyptian infants with protein calorie malnutrition to hepatitis B vaccination. *J Trop Pediatr* 1996; **42**(3): 144-145.
- [18] Banatvala JE, Van Damme P. Hepatitis B vaccine-do we need boosters? *J Viral Hepat* 2003; **10**(1): 1-6.
- [19] Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X, et al. Revaccination of non- and low-responders after a standard three dose hepatitis B vaccine schedule. *Hum Vaccin Immunother* 2012; **8**(12): 1845-1849.
- [20] Pracoyo NE, Wibowo. Factors related with immunity against hepatitis B (anti-HBs) in children aged 1-14 years obtained from general health research data 2007. *Media Litbangkes* 2016; **26**: 59-64.
- [21] Cochrane Collaboration. *2016-Optimizing the hepatitis B vaccination schedules: Systematic review of safety and efficacy of childhood schedules using hepatitis B containing vaccines*. London: WHO SAGE Meet Oct 2016. [Online]. Available from: http://www.who.int/immunization/sage/meetings/2016/october/4_Systematic_review_of_safety_efficacy_hep_b.pdf. [Accessed on 6 June 2020].
- [22] Aswati L, Jurnalis YD, Sayoeti Y, Bachtiar H. Factors related with anti-HBs titer in elementary school children after 10-12 years hepatitis B vaccination in Padang city. *Sari Pediatr* 2013; **14**(5): 303-308.
- [23] World Health Organization. Hepatitis B vaccines. *Wkly Epidemiol Rec* 2017; **92**(27): 369-392.
- [24] Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. *J Viral Hepat* 2011; **18**(5): 369-375.
- [25] Immunization Action Coalition. *Unprotected people # 45 hepatitis B*. [Online]. Available from: <https://www.immunize.org/reports/report045.pdf>. [Accessed on 28 January 2021].
- [26] Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. *Trop Med Int Health* 2006; **11**(10): 1496-1502.
- [27] Mollica F, Musumeli S, Rugolo S, Mattina T. A prospective study of 18 infants of chronic HBsAg mothers. *Arch Dis Child* 1979; **54**(10): 750-754.
- [28] Nelson NP, Jamieson DJ, Murphy TV. Prevention of perinatal hepatitis B virus transmission. *J Pediatric Infect Dis Soc* 2014; **3**(Suppl 1): S7-S12.
- [29] Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at

- birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: A randomized controlled trial. *J Viral Hepat* 2013; **20**(11): 801-810.
- [30]Health Office of Surabaya City. *Health profile of Surabaya City 2016*. [Online]. Available from: [http://dinkes.surabaya.go.id/portalv2/dokumen/Profil Kesehatan Kota Surabaya 2016.pdf](http://dinkes.surabaya.go.id/portalv2/dokumen/Profil%20Kesehatan%20Kota%20Surabaya%202016.pdf). [Accessed on 6 June 2020].
- [31]World Health Organization. *WHO child growth standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development*. [Online]. Available from: <https://apps.who.int/iris/handle/10665/43413>. [Accessed on 6 June 2020].
- [32]Ministry of Health Republic of Indonesia. *Immunization implementation guidelines 2004*. [Online]. Available from: <http://hukor.depkes.go.id>. [Accessed on 28 January 2020].
- [33]Center of Data and Information Ministry of Health Republic of Indonesia. *Hepatitis situation and analysis 2014*. [Online]. Available from: <https://pusdatin.kemkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-hepatitis.pdf>. [Accessed on 6 June 2020].
- [34]Pronocitro C, Mulyani NS, Ghufroon AA, Hazazi YH, Ardianto B, Heriyanto DS. Efficacy of hepatitis B vaccination among children in special region of Yogyakarta, Indonesia: Evaluation of humoral and cellular immunity. *Kobe J Med Sci* 2017; **63**(3): E92-E98.
- [35]Hazazi YH. *Relation between age and anti-HBs titer in children with complete hepatitis B vaccination*. BSc. Thesis. Yogyakarta: Gadjah Mada University; 2015.
- [36]Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. *J Pediatr* 1995; **126**(5 Pt 1): 716-721.
- [37]Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. *J Infect Dis* 2003; **187**(1): 134-138.
- [38]Zimmermann P, Curtisa N. Factors that influence the immune response to vaccination. *Clin Microbiol Rev* 2019; **32**: e00084-18. doi: 10.1128/CMR.00084-18.
- [39]Aghakhani A, Banifazl M, Izadi N, McFarland W, Sofian M, Khadem-Sadegh A, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. *World J Pediatr* 2011; **7**(4): 358-360.
- [40]Rezaei M, Nooripoor S, Ghorbani R, Ramezanshams F, Mamishi S, Mahmoudi S. Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan. *J Prev Med Hyg* 2014; **55**: 1-3.
- [41]Kwon J, Jeong SJ. Association between body mass index and hepatitis B antibody seropositivity in children. *Korean J Pediatr* 2019; **62**(11): 416-421. doi: 10.3345/kjp.2019.00563.
- [42]Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, et al. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. *J Infect Dis* 2013; **207**(3): 402-410.
- [43]Wang H, Cai B, Rao D, Liu M, Li Y, Liang X, et al. Rapid immunization effects of a new type of 60 µg hepatitis B vaccine compared with traditional 20 µg hepatitis B vaccines in adults. *Hum Vaccines Immunother* 2016; **12**(11): 2921-2926.
- [44]Rampengan NH, Hadinegoro SR, Karyanti MR. Hepatitis B seroprotection in children aged 10-15 years after completion of basic hepatitis B immunizations. *Paediatr Indone* 2017; **57**(2): 76-83.
- [45]World Health Organization, Regional Office for the Western Pacific. *Hepatitis B control through immunization: A reference guide*. Manila: WHO Regional Office for the Western Pacific; 2014, p. 50.
- [46]Centers for Disease Control and Prevention. Progress in hepatitis B prevention through universal infant vaccination-China, 1997-2006. *JAMA* 2007; **298**(5): 506-509. doi: 10.1001/jama.298.5.506.
- [47]Wiese-Posselt M, Tertilt C, Zepp F. Vaccination recommendations for Germany. *Dtsch Arztebl Int* 2011; **108**(45): 771-780.
- [48]Center for Disease Control and Prevention. *Morbidity and mortality weekly report a comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the advisory committee*. [Online]. Available from: <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm>. [Accessed on 28 January 2021].
- [49]Coursaget P, Yvonnet B, Chotard J, Sarr M, Vincelot P, N'doye R, et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). *Lancet* 1986; **2**(8516): 1143-1145.
- [50]Lee KH, Shim KS, Lim IS, Chae SA, Yun SW, Lee NM, et al. Changes in hepatitis B virus antibody titers over time among children: A single center study from 2012 to 2015 in an urban of South Korea. *BMC Pediatr* 2017; **17**(1): 164.
- [51]Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. *Pediatr Infect Dis* 2004; **23**(7): 650-655.
- [52]Li X, Xu Y, Dong Y, Yang X, Ye B, Wang Y, et al. Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children: Protective anti-HBs levels and cellular immune responses. *Vaccine* 2018; **36**(18): 2442-2449.
- [53]Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. *Hepatology* 2010; **51**(5): 1547-1554.
- [54]Gu H, Yao J, Zhu W, Lv H, Cheng S, Ling L, et al. The effects of booster vaccination on hepatitis B vaccine in anti-HBs negative infants of HBsAg-positive mothers after primary vaccination. *Hum Vaccines Immunother* 2013; **9**(6): 1292-1295.
- [55]Chang YC, Wang JH, Chen YS, Lin JS, Cheng CF, Chu CH. Hepatitis B virus vaccination booster does not provide additional protection in adolescents: A cross-sectional school-based study. *BMC Public Health* 2014; **14**: 1-11.
- [56]Liu J, Lv J, Yan B, Feng Y, Song L, Xu A, et al. Comparison between two population-based hepatitis B serosurveys with an 8-year interval in Shandong Province, China. *Int J Infect Dis* 2017; **61**:13-19.
- [57]Cabezas C, Trujillo O, Balbuena J, de Maria Peceros F, Terrazas M, Suárez M, et al. Decrease in the prevalence of hepatitis B and D virus infections in an endemic area in Peru 23 years after the introduction of the first pilot vaccination program against hepatitis B. *PLoS One* 2020; **15**(8): e0236993.